DYN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
197.4M
+8.6%
181.7M
+45.0%
125.3M
+7.9%
116.1M
+2.2%
113.6M
R&D
161.7M
+6.3%
152.2M
+50.8%
100.9M
+5.7%
95.4M
-1.8%
97.2M
SG&A
35.3M
+19.8%
29.5M
+20.9%
24.4M
+17.8%
20.7M
+24.1%
16.7M
Operating Income
-197370000
-8.6%
-181661000
-45.0%
-125276000
-7.9%
-116129000
-2.2%
-113613000
EBITDA
-196729000
-8.6%
-181101000
-45.2%
-124726000
-7.9%
-115608000
-2.2%
-113090000
Net Income
-193552000
-8.4%
-178556000
-47.7%
-120854000
-7.9%
-111955000
-3.6%
-108041000
EPS (Basic)
$-1.06
+1.9%
$-1.08
-47.9%
$-0.73
+3.9%
$-0.76
+0.0%
$-0.76
EPS (Diluted)
$-1.06
+1.9%
$-1.08
-47.9%
$-0.73
+3.9%
$-0.76
+0.0%
$-0.76
Shares (Diluted)
181.8M
+9.9%
165.5M
+0.3%
165.0M
+11.4%
148.2M
+4.5%
141.8M
Dyne Therapeutics (DYN) — Financials